BRENTWOOD, Tenn., Oct. 22, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) will release its third quarter 2025 financial results after the close of the market on Thursday, November 6, 2025. In conjunction with this release, the Company will hold a conference call on Friday, November 7, 2025, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time) to discuss financial results.
A live webcast of the conference call can be accessed at brookdaleinvestors.com. Please allow extra time before the call to download the necessary software required to listen to the internet broadcast. A replay of the webcast will be available at brookdaleinvestors.com shortly after the conclusion of the event.
About Brookdale Senior Living
Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. With 623 communities across 41 states and the ability to serve approximately 57,000 residents as of September 30, 2025, Brookdale is committed to its mission of enriching the lives of seniors through compassionate care, clinical expertise, and exceptional service. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities, offering tailored solutions that help empower seniors to live with dignity, connection, and purpose. Leveraging deep expertise in healthcare, hospitality, and real estate, Brookdale creates opportunities for wellness, personal growth, and meaningful relationships in settings that feel like home. Guided by its four cornerstones of passion, courage, partnership, and trust, Brookdale is committed to delivering exceptional value and redefining senior living for a brighter, healthier future. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit brookdale.com or connect with Brookdale on Facebook or YouTube.

| Last Trade: | US$8.83 |
| Daily Change: | 0.11 1.26 |
| Daily Volume: | 1,878,458 |
| Market Cap: | US$2.100B |
October 08, 2025 October 02, 2025 September 18, 2025 September 09, 2025 August 06, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load